Perspective Therapeutics, Inc. (NYSE:CATX) Receives $15.13 Consensus Target Price from Analysts

Perspective Therapeutics, Inc. (NYSE:CATX) has been given an average rating of “Buy” by the twelve analysts that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation, eight have given a buy recommendation and three have assigned a strong buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $14.56.

A number of brokerages have recently weighed in on CATX. Brookline Capital Management upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a research note on Monday, March 10th. Scotiabank started coverage on Perspective Therapeutics in a research report on Friday, March 7th. They issued a “sector outperform” rating and a $15.00 price target on the stock. Lifesci Capital raised Perspective Therapeutics to a “strong-buy” rating in a research report on Thursday, March 6th. HC Wainwright started coverage on Perspective Therapeutics in a report on Thursday. They issued a “buy” rating and a $10.00 target price on the stock. Finally, Cantor Fitzgerald raised Perspective Therapeutics to a “strong-buy” rating in a research report on Tuesday, March 4th.

Perspective Therapeutics Price Performance

Shares of CATX stock opened at $2.59 on Monday. The stock’s 50 day simple moving average is $3.14 and its 200 day simple moving average is $7.20. Perspective Therapeutics has a twelve month low of $2.32 and a twelve month high of $19.05.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. The Manufacturers Life Insurance Company raised its stake in shares of Perspective Therapeutics by 8.9% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 20,514 shares of the company’s stock valued at $274,000 after buying an additional 1,672 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Perspective Therapeutics by 5.8% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 58,678 shares of the company’s stock worth $783,000 after purchasing an additional 3,211 shares during the period. BNP Paribas Financial Markets boosted its holdings in Perspective Therapeutics by 7.4% during the fourth quarter. BNP Paribas Financial Markets now owns 51,094 shares of the company’s stock valued at $163,000 after purchasing an additional 3,529 shares in the last quarter. US Bancorp DE grew its stake in shares of Perspective Therapeutics by 142.7% in the 3rd quarter. US Bancorp DE now owns 6,576 shares of the company’s stock valued at $88,000 after purchasing an additional 3,866 shares during the period. Finally, Rhumbline Advisers raised its holdings in shares of Perspective Therapeutics by 4.5% in the 4th quarter. Rhumbline Advisers now owns 94,992 shares of the company’s stock worth $303,000 after buying an additional 4,075 shares in the last quarter. 54.66% of the stock is owned by institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.